Short answer
ANAPTYSBIO, INC (ANAB) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 7.01 (Regulation FD Disclosure). Delaware Chancery litigation remains unresolved after July 14-17, 2026 trial.
ANAPTYSBIO, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Delaware Chancery litigation remains unresolved after July 14-17, 2026 trial
- AnaptysBio alleges Tesaro breached the collaboration agreement and GSK tortiously interfered
- Post-trial briefing schedule extends through October 9, 2026
- Post-trial argument scheduled for October 20, 2026
- Outcome could affect AnaptysBio’s collaboration rights and potential litigation-related recovery or exposure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAPTYSBIO, INC 8-K filings
Get the next ANAB 8-K as it lands
Follow ANAB for push alerts, or ask the research agent what this filing means.